In this issue:
- Durvalumab: 5-year survival outcomes
- Adagrasib for KRAS G12C mutation NSCLC
- PD-L1 inhibitors ± platinumdoublet chemotherapy
- BRAF-altered tumours:Immune biomarkers
- Nivolumab + ipilimumab for pleural mesothelioma
- BMI and NSCLC risk
- COVID-19 and lung cancer care for Māori
- SCLC: patterns of presentation
- Clinical quality indicators and oncological surgery
- Biomarkers for indeterminate pulmonary nodules
Please login below to download this issue (PDF)